HIV AIDS pathophysiology: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
m (Bot: Removing from Primary care)
 
(101 intermediate revisions by 13 users not shown)
Line 1: Line 1:
<div style="-webkit-user-select: none;">
{|class="infobox" style="position: fixed; top: 65%; right: 10px; margin: 0 0 0 0; border: 0; float: right;
|-
| {{#ev:youtube|https://https://www.youtube.com/watch?v=5g1ijpBI6Dk|350}}
|-
|}
__NOTOC__
__NOTOC__
{{AIDS}}
{{AIDS}}


{{CMG}}
{{CMG}}; {{AE}} {{Ammu}}, {{JH}}
==Overview==
==Overview==
Human Immunodeficiency virus causes AIDS by depleting [[CD4+]] [[T helper]] [[lymphocyte]]s. T lymphocytes are essential to the immune response and without them, the body cannot fight infections or kill [[cancer]]ous cells. Thus the weakened [[immune system]] allows [[opportunistic infection]]s and [[neoplastic]] processes. The mechanism of CD4+ T cell depletion differs in the [[acute]] and [[chronic]] phases, to sum it all AIDS has a complex pathophysiology.<ref name="pmid8040596">{{cite journal |author=Guss DA |title=The acquired immune deficiency syndrome: an overview for the emergency physician, Part 1 |journal=J Emerg Med |volume=12 |issue=3 |pages=375–84 |year=1994 |pmid=8040596 |doi= |url= |accessdate=2012-04-27}}</ref> To read about the progression of HIV infection to AIDS, click [[HIV infection pathophysiology|here]]
HIV causes acquired immunodeficiency syndrome by depleting [[CD4+]] [[T helper cells|T helper]] [[lymphocytes]]. The virus is acquired by either sexual contact, exposure to contaminated blood, or [[vertical transmission|mother-to-child transmission]]. Once the virus is acquired, it disseminates to the majority of [[lymphoid organs]], where it enters a period of rapid [[viral replication]]. This leads to the acute phase of the infection, which is characterized by a very elevated viral titer and an acute drop in [[T helper cells|CD4 T-lymphocyte]] count. As the immune response mounts, viral replication and the CD4-cell depletion rate drops. The immune system continues to deteriorate, but at a slower pace. This is known as the chronic phase of HIV infection. The HIV virus causes CD4-cell death by a variety of mechanisms including cytopathic single-cell destruction, syncytia formation, [[autoimmunity]], and superantigen formation.<ref name="pmid8093551">{{cite journal| author=Pantaleo G, Graziosi C, Fauci AS| title=New concepts in the immunopathogenesis of human immunodeficiency virus infection. | journal=N Engl J Med | year= 1993 | volume= 328 | issue= 5 | pages= 327-35 | pmid=8093551 | doi=10.1056/NEJM199302043280508 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8093551  }} </ref>


==Pathophysiology==
==Pathophysiology==
* The pathophysiologic progression from acute HIV infection to AIDS is described in the chapter [[HIV infection pathophysiology]]. This chapter explains the pathophysiology of AIDS.
* The specific decline in CD4<sup>4</sup> helper T cells, result in inversion of the normal CD4/[[CD8]] T cell ratio. It also cause dysregulation of [[B cell]] [[antibody]] production.<ref name="pmid3498182">{{cite journal |author=Frazer IH, Mackay IR, Crapper RM, Jones B, Gust ID, Sarngadharan MG, Campbell DC, Ungar B |title=Immunological abnormalities in asymptomatic homosexual men: correlation with antibody to HTLV-III and sequential changes over two years |journal=Q. J. Med. |volume=61 |issue=234 |pages=921–33 |year=1986 |month=October |pmid=3498182 |doi= |url=http://qjmed.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=3498182 |accessdate=2012-05-24}}</ref><ref name="pmid2966631">{{cite journal |author=Schechter MT, Boyko WJ, Craib KJ, McLeod A, Willoughby B, Douglas B, Constance P, O'Shaughnessey M |title=Effects of long-term seropositivity to human immunodeficiency virus in a cohort of homosexual men |journal=AIDS |volume=1 |issue=2 |pages=77–82 |year=1987 |month=July |pmid=2966631 |doi= |url= |accessdate=2012-05-24}}</ref>
* B cell exhibit increased expression of markers of activation and [[proliferation]].<ref name="pmid15508184">{{cite journal |author=Moir S, Malaspina A, Pickeral OK, Donoghue ET, Vasquez J, Miller NJ, Krishnan SR, Planta MA, Turney JF, Justement JS, Kottilil S, Dybul M, Mican JM, Kovacs C, Chun TW, Birse CE, Fauci AS |title=Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily |journal=J. Exp. Med. |volume=200 |issue=7 |pages=587–99 |year=2004 |month=October |pmid=15508184 |doi= |url=http://www.jem.org/cgi/pmidlookup?view=long&pmid=15508184 |accessdate=2012-05-25}}</ref> Terminal differentiation of B cell leads to increased immunoglobulin secretion, which further causes [[polyclonal]] [[hypergammaglobulinemia]] producing non-specific antibodies.<ref name="pmid11504927">{{cite journal |author=Moir S, Malaspina A, Ogwaro KM, Donoghue ET, Hallahan CW, Ehler LA, Liu S, Adelsberger J, Lapointe R, Hwu P, Baseler M, Orenstein JM, Chun TW, Mican JA, Fauci AS |title=HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=98 |issue=18 |pages=10362–7 |year=2001 |month=August |pmid=11504927 |pmc=56966 |doi=10.1073/pnas.181347898 |url=http://www.pnas.org/cgi/pmidlookup?view=long&pmid=11504927 |accessdate=2012-05-25}}</ref> This also explain the reason for increases risk of [[bacteria]]l [[infection]] inspite of high circulating levels of [[immunoglobulin]]s.
* The immune response to [[antigen]]s begins to decline, as a result, the host fails to respond adequately to [[opportunistic infection]]s and normally harmless [[commensal]]s.
* The infections tend to be non-[[bacterial]] (i.e [[fungal]], [[Viral]]) because the defect preferentially involves [[cellular immunity]].
*Humoral immunity generally improves dramatically after the initiation of ART.


===Role of [[GALT]] in [[Pathogenesis]]===
===HIV transmission===
*Port of entry for HIV infection, is mostly through direct blood [[inoculation]] or exposure through [[genital]] [[mucosa]]l surface. The [[gastrointestinal tract]] contains a large amount of [[lymphoid tissue]], making it an ideal place for [[replication]] of Human Immunodeficiency Virus. [[GALT]] plays a role in HIV replication. <ref name="pmid11242193">{{cite journal |author=Talal AH, Irwin CE, Dieterich DT, Yee H, Zhang L |title=Effect of HIV-1 infection on lymphocyte proliferation in gut-associated lymphoid tissue |journal=J. Acquir. Immune Defic. Syndr. |volume=26 |issue=3 |pages=208–17 |year=2001 |month=March |pmid=11242193 |doi= |url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=1525-4135&volume=26&issue=3&spage=208 |accessdate=2012-05-25}}</ref>
{{#widget:BlueTable}}
* GALT has been found to have the following characteristics:
{| class="BlueTable" style=" width: 400px; float:right"
**Site of early viral seeding.
|-
**Establishment of the pro-viral [[natural reservoir|reservoir]].
|+'''Estimated risk for acquisition of HIV-1 by exposure route'''<ref name=MMWR>{{cite journal | author=Smith, D. K., Grohskopf, L. A., Black, R. J., Auerbach, J. D., Veronese, F., Struble, K. A., Cheever, L., Johnson, M., Paxton, L. A., Onorato, I. A. and Greenberg, A. E. | title=Antiretroviral Postexposure Prophylaxis After Sexual, Injection-Drug Use, or Other Nonoccupational Exposure to HIV in the United States | journal=MMWR | year=2005 | pages=1-20 | volume=54 | issue=RR02 | url=http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5402a1.htm#tab1}}</ref>
*The proviral GALT reservoir contributes to the following:
! '''Exposure Route'''
#Difficulty in controlling the infection.
! '''Estimated infections<br/>per 10,000 exposures<br/>to an infected source'''
#Difficulty in reducing the level of HIV provirus through sustained ART.<ref name="pmid16936559">{{cite journal |author=Poles MA, Boscardin WJ, Elliott J, Taing P, Fuerst MM, McGowan I, Brown S, Anton PA |title=Lack of decay of HIV-1 in gut-associated lymphoid tissue reservoirs in maximally suppressed individuals |journal=J. Acquir. Immune Defic. Syndr. |volume=43 |issue=1 |pages=65–8 |year=2006 |month=September |pmid=16936559 |doi=10.1097/01.qai.0000230524.71717.14 |url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=1525-4135&volume=43&issue=1&spage=65 |accessdate=2012-05-25}}</ref> Various studies measuring the CD4<sup>4</sup> in GALT, have shown the relatively less reconstitution with ART, than that observed in peripheral blood.<ref name="pmid14557656">{{cite journal |author=Guadalupe M, Reay E, Sankaran S, Prindiville T, Flamm J, McNeil A, Dandekar S |title=Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy |journal=J. Virol. |volume=77 |issue=21 |pages=11708–17 |year=2003 |month=November |pmid=14557656 |pmc=229357 |doi= |url=http://jvi.asm.org/cgi/pmidlookup?view=long&pmid=14557656 |accessdate=2012-05-25}}</ref><ref name="pmid12719554">{{cite journal |author=Shacklett BL, Cox CA, Sandberg JK, Stollman NH, Jacobson MA, Nixon DF |title=Trafficking of human immunodeficiency virus type 1-specific CD8+ T cells to gut-associated lymphoid tissue during chronic infection |journal=J. Virol. |volume=77 |issue=10 |pages=5621–31 |year=2003 |month=May |pmid=12719554 |pmc=154016 |doi= |url=http://jvi.asm.org/cgi/pmidlookup?view=long&pmid=12719554 |accessdate=2012-05-25}}</ref>
|-
| Blood Transfusion
| align="center" | 9,000<ref name=Donegan>{{cite journal
| author=Donegan, E., Stuart, M., Niland, J. C., Sacks, H. S., Azen, S. P., Dietrich, S. L., Faucett, C., Fletcher, M. A., Kleinman, S. H., Operskalski, E. A., et al.
| title=Infection with human immunodeficiency virus type 1 (HIV-1) among recipients of antibody-positive blood donations
| journal=Ann. Intern. Med.
| year=1990
| pages=733-739
| volume=113
| issue=10
| pmid=2240875
}}</ref>
|-
| Childbirth
| align="center" | 2,500<ref name=Coovadia>{{cite journal
| author=Coovadia, H.
| title=Antiretroviral agents&mdash;how best to protect infants from HIV and save their mothers from AIDS | journal=N. Engl. J. Med.
| year=2004
| pages=289-292
| volume=351
| issue=3
| pmid=15247337
| format=
}}</ref>
|-
| Needle-sharing injection drug use
| align="center" | 67<ref name=Kaplan>{{cite journal | author=Kaplan, E. H. and Heimer, R. | title=HIV incidence among New Haven needle exchange participants: updated estimates from syringe tracking and testing data | journal=J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. | year=1995 | pages=175-176 | volume=10 | issue=2
| pmid=7552482 }}</ref>
|-
| Receptive anal intercourse<sup>¶</sup>
| align="center" | 50<ref name=ESG>{{cite journal | author=European Study Group on Heterosexual Transmission of HIV | title=Comparison of female to male and male to female transmission of HIV in 563 stable couples | journal=BMJ. | year=1992 | pages=809-813 | volume=304 | issue=6830 | pmid=1392708 |format=}}</ref><ref name=Varghese>{{cite journal | author=Varghese, B., Maher, J. E., Peterman, T. A., Branson, B. M. and Steketee, R. W. | title=Reducing the risk of sexual HIV transmission: quantifying the per-act risk for HIV on the basis of choice of partner, sex act, and condom use | journal=Sex. Transm. Dis. | year=2002 | pages=38-43 | volume=29 | issue=1 | pmid=11773877 |format=}}</ref>
|-
| Percutaneous needle stick
| align="center" | 30<ref name=Bell>{{


==Coinfections==
cite journal | author=Bell, D. M. | title=Occupational risk of human immunodeficiency virus infection in healthcare workers: an overview. | journal=Am. J. Med. | year=1997 | pages=9-15 | volume=102 | issue=5B | pmid=9845490
===Effect of Geographic Area on Opportunistic Infection===
The opportunistic infection in AIDS patient reflect the pathogen that are common in that area.
* '''In USA:''' Person with AIDS tends to present with commensal organism such as [[Pneumocystis pneumonia|Pneumoncystis]] and [[Candida]].
** In a study done by National Center of HIV/AIDS,<ref name="pmid12412613">{{cite journal |author=Jones JL, Hanson DL, Dworkin MS, Alderton DL, Fleming PL, Kaplan JE, Ward J |title=Surveillance for AIDS-defining opportunistic illnesses, 1992-1997 |journal=MMWR CDC Surveill Summ |volume=48 |issue=2 |pages=1–22 |year=1999 |month=April |pmid=12412613 |doi= |url= |accessdate=2012-05-25}}</ref> PCP was the most common AIDS-defining opportunistic infection to occur first.
*** PCP was the first OI to occur for 36% of HIV-infected persons.
*** The most common incident AIDS-defining OI (274 cases per 1000 person-years).
*** The most common AIDS-defining OI to have occurred during the course of AIDS (53% of persons who died with AIDS had PCP diagnosed at some time during their course of AIDS).
* '''In developing nations:''' AIDS patients tends to present with [[Tuberculosis]], as it is more prevalent in those countries.


===A. The Major Pulmonary illnesses ===
}}</ref>
<gallery>  
|-
Image:Pneumocystis_jiroveci.jpg|Pneumocystis jiroveci is present in this lung impression smear, using [[Giemsa stain]]
| Receptive penile-vaginal intercourse<sup>¶</sup>
Image:Tuberculosis_SEM.jpg|Scanning electron micrograph (SEM) of a number of [[Gram-positive]] Mycobacterium tuberculosis bacteria
| align="center" | 10<ref name=ESG /><ref name=Varghese /><ref name=Leynaert>{{
</gallery>


===Pneumocystis jiroveci pneumonia ===
cite journal | author=Leynaert, B., Downs, A. M. and de Vincenzi, I. | title=Heterosexual transmission of human immunodeficiency virus: variability of infectivity throughout the course of infection. European Study Group on Heterosexual Transmission of HIV | journal=Am. J. Epidemiol. | year=1998 | pages=88-96 | volume=148 | issue=1 | pmid=9663408
Pneumocystis jiroveci pneumonia (originally known as Pneumocystis carinii pneumonia, often abbreviated PCP) is relatively rare in normal, immunocompetent people but common among HIV-infected individuals. Before the advent of effective treatment and diagnosis in Western countries it was a common immediate cause of death.
In developing countries, it is still one of the first indications of AIDS in untested individuals, although it does not generally occur unless the CD4 count is less than 200 per µl (Feldman, 2005).


==== Tuberculosis ====
}}</ref>
Among infections associated with HIV, [[Tuberculosis]] (TB) is unique in that it may be transmitted to immunocompetent persons via the respiratory route, is easily treatable once identified, may occur in early-stage HIV disease, and is preventable with drug therapy. However, multi-drug resistance is a potentially serious problem. Even though its incidence has declined because of the use of directly observed therapy and other improved practices in Western countries, this is not the case in developing countries where HIV is most prevalent. In early-stage HIV infection (CD4 count >300 cells per µl), TB typically presents as a pulmonary disease.
|-
In advanced HIV infection, TB may present atypically and extrapulmonary TB is common infecting bone marrow, bone, urinary and gastrointestinal tracts, liver, regional lymph nodes, and the central nervous system (Decker and Lazarus, 2000).
| Insertive anal intercourse<sup>¶</sup>
| align="center" | 6.5<ref name=ESG /><ref name=Varghese />
|-
| Insertive penile-vaginal [[sexual intercourse|intercourse]]<sup>¶</sup>
| align="center" | 5<ref name=ESG /><ref name=Varghese />
|-
| Receptive fellatio<sup>¶</sup>
| align="center" | 1<ref name=Varghese />
|-
| Insertive fellatio<sup>¶</sup>
| align="center" | 0.5<ref name=Varghese />
|- bgcolor="#efefef"
|style="background: #DCDCDC" colspan=2 | <sup>¶</sup> Assuming no condom use.
|}
Since the beginning of the [[pandemic]], three main transmission routes for HIV have been identified: sexual route, blood or blood product route, and mother-to-child transmission. <br>
'''Sexual route'''
*The majority of HIV infections are acquired through unprotected sexual relations. Sexual transmission can occur when infected sexual secretions of one partner come into contact with the genital, oral, or rectal [[mucous membranes]] of another.


===B. The Major Gastro-Intestinal illnesses ===
'''Blood or blood product route'''
*This transmission route can account for infections in intravenous drug users, [[hemophiliac]]s and recipients of [[blood transfusion]]s (though most transfusions are checked for HIV in the developed world) and blood products.
*It is also of concern for persons receiving medical care in regions where there is prevalent substandard hygiene in the use of injection equipment, such as the reuse of needles in Third World countries. HIV can also be spread through the sharing of needles.
*Health care workers such as nurses, laboratory workers, and doctors, have also been infected, although this occurs more rarely. People who give and receive tattoos, piercings, and scarification procedures can also be at risk of infection.


==== Esophagitis ====
'''Mother-to-child transmission (MTCT)'''
*The transmission of the virus from the mother to the child can occur ''in utero'' during pregnancy and ''intrapartum'' at childbirth. In the absence of treatment, the transmission rate between the mother and child is around 25%.<ref name=Coovadia /> However, where combination [[antiretroviral]] drug treatment and [[Cesarian section]] are available, this risk can be reduced to as low as 1%.<ref name=Coovadia /> Breast feeding also presents a risk of infection for the baby.
*HIV-2 is transmitted much less frequently by the MTCT and sexual route than HIV-1.


[[Esophagitis]] is an [[inflammation]] of the lining of the lower end of the [[esophagus]] (gullet or swallowing tube leading to the stomach). In HIV infected individuals, this could be due to fungus ([[candidiasis]]), virus (herpes simplex-1 or cytomegalovirus). In rare cases, it could be due to [[mycobacteria]] (Zaidi and Cervia, 2002).
'''Other Considerations'''
*HIV has been found at low concentrations in the [[saliva]], [[tears]] and [[urine]] of infected individuals, but there are no recorded cases of infection by these secretions and the potential risk of transmission is negligible.<ref name="pmid2963151">{{cite journal
|author=Lifson AR
|title=Do alternate modes for transmission of human immunodeficiency virus exist? A review
|journal=JAMA
|volume=259
|issue=9
|pages=1353–6
|year=1988
|pmid=2963151
|doi=
}}</ref>
*The use of physical barriers such as the latex [[condom]] is widely advocated to reduce the sexual transmission of HIV. [[Spermicide]], when used alone or with vaginal contraceptives like a [[diaphragm (contraceptive)|diaphragm]], actually increases the male to female transmission rate due to inflammation of the vagina; it should not be considered a barrier to infection.<ref name="spermicide">{{cite web |url=http://www.fda.gov/oashi/aids/condom.html#should |title=Should spermicides be used with condoms? |accessdate=2006-10-23 |work=Condom Brochure, FDA OSHI HIV STDs }}</ref>
*A panel of experts convened by WHO and the UNAIDS Secretariat has "recommended that male circumcision now be recognized as an additional important intervention to reduce the risk of heterosexually acquired HIV infection in men."<ref name=WHOUNAIDScircum>{{


==== Unexplained Chronic Diarrhea ====
cite web
| author=WHO | publisher=WHO.int | year=2007
| url=http://www.who.int/hiv/mediacentre/news68/en/index.html
| title=WHO and UNAIDS announce recommendations from expert consultation on male circumcision for HIV prevention
| accessdate=2007-07-13


In HIV infection, there are many possible causes of [[diarrhea]], including common bacterial (Salmonella, Shigella, Listeria, Campylobacter, or Escherichia coli) and [[parasitic infections]], and uncommon [[opportunistic infections]] such as cryptosporidiosis, microsporidiosis, Mycobacterium avium complex (MAC) and cytomegalovirus (CMV) colitis. Diarrhea may follow a course of [[antibiotics]] (common for Clostridium difficile). It may also be a side effect of several drugs used to treat HIV, or it may simply accompany HIV infection, particularly during primary HIV infection. In the later stages of HIV infection, diarrhea is thought to be a reflection of changes in the way the intestinal tract absorbs nutrients, and may be an important component of HIV-related wasting (Guerrant et al., 1990).
}}</ref>
*Research is clarifying whether there is a historical relationship between rates of male circumcision and rates of HIV in differing social and cultural contexts. Previously, Siegfried ''et al.'' suggested that it was possible that the correlation between circumcision and HIV in observational studies may be due to [[Confounding variable|confounding factors]], and remarked that the randomized controlled trials would therefore provide "essential evidence" about the effects of circumcision.<ref name=Siegfred>


===C. The Major Neurological illnesses ===
{{cite journal
| author=Siegfried, N., Muller, M., Deeks, J., Volmink, J., Egger, M., Low, N., Walker, S. and Williamson, P. | title=HIV and male circumcision--a systematic review with assessment of the quality of studies | journal=Lancet Infect. Dis. | year=2005 | pages=165-173 | volume=5 | issue=3 | pmid=15766651


==== Toxoplasmosis ====
}}</ref>
[[Image:Toxoplasmosi_AIDS.jpg|thumb|left|Toxoplasmosis of heart in AIDS]]
*There is little data on circumcision's effect on HIV risk with homosexual men and it is still being studied. A study of foreign and American men by scientists at the University of Washington, Seattle concluded: "Uncircumcised homosexual men in Seattle had a two fold increased risk of HIV infection.
[[Toxoplasmosis]] is a disease caused by the single-celled parasite called Toxoplasma gondii. T. gondii usually infects the brain causing toxoplasma encephalitis. It can also infect and cause disease in the eyes and lungs (Luft and Chua, 2000).
*If the relative risk that we observed in Seattle were also present in other populations, the population attributable risk of uncircumcised status for HIV in homosexual men would be 40%, i.e., 40% of homosexual transmission of HIV could be potentially preventable with universal circumcision."[http://gateway.nlm.nih.gov/MeetingAbstracts/102199521.html]
* A study of Australian men headed by David Templeton, MD, from the University of New South Wales found "no relationship at all between circumcision and HIV seroconversion in" homosexual men. Templeton theorizes that this may be because most HIV occurs "following receptive rather than insertive intercourse," as he finds data on circumcision's effect on heterosexual men "compelling".<ref>http://www.medscape.com/viewarticle/560823</ref> South African medical experts are concerned that the repeated use of unsterilized blades in the [[Circumcision#Cultures and religions|ritual]] (not medical) circumcision of adolescent boys may be spreading HIV.<ref name=Kaisercircum>{{


==== Progressive Multifocal Leukoencephalopathy ====
cite web
| author=Various | publisher=Kaisernetwork.org | year=2005
| url=http://www.kaisernetwork.org/daily_reports/rep_index.cfm?DR_ID=31199
| title=Repeated Use of Unsterilized Blades in Ritual Circumcision Might Contribute to HIV Spread in S. Africa, Doctors Say
| accessdate=2006-03-28


Progressive multifocal leukoencephalopathy ([[PML]]) is a demyelinating disease, in which the [[myelin]] sheath covering the axons of nerve cells is gradually destroyed, impairing the transmission of nerve impulses. It is caused by a virus called JC virus which occurs in 70% of the population in latent form, causing disease only when the immune system has been severly weakened, as is the case for AIDS patients. It progresses rapidly, usually causing death within months of diagnosis (Sadler and Nelson, 1997).
}}</ref>


==== HIV-associated Dementia ====
===Viral Pathogenesis===
After the virus is acquired, a period of rapid [[viral replication]] ensues, leading to abundant viremia. During primary infection, the level of HIV may reach several million virus particles per milliliter of blood.<ref name=Piatak>{{cite journal | author=Piatak, M., Jr, Saag, M. S., Yang, L. C., Clark, S. J., Kappes, J. C., Luk, K. C., Hahn, B. H., Shaw, G. M. and Lifson, J.D. | title=High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR|journal=Science | year=1993 |pages=1749–1754 |volume=259 | issue=5102 | pmid=8096089 |doi=10.1126/science.8096089|bibcode = 1993Sci...259.1749P }}</ref>  This response is accompanied by a marked drop in the numbers of circulating CD4<sup>+</sup> T cells. This acute viremia is associated in virtually all people with the activation of [[cytotoxic T cell|CD8<sup>+</sup> T cells]], which kill HIV-infected cells, and subsequently with antibody production, or [[seroconversion]]. The CD8<sup>+</sup> T cell response is thought to be important in controlling virus levels, which peak and then decline, as the CD4<sup>+</sup> T cell counts rebound. A good CD8<sup>+</sup> T cell response has been linked to slower disease progression and a better prognosis, though it does not eliminate the virus.<ref name=Pantaleo1998>{{cite journal| author=Pantaleo G, Demarest JF, Schacker T, Vaccarezza M, Cohen OJ, Daucher M, Graziosi C, Schnittman SS, Quinn TC, Shaw GM, Perrin L, Tambussi G, Lazzarin A, Sekaly RP, Soudeyns H, Corey L, Fauci AS. | title=The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia | journal=Proc Natl Acad Sci U S A. | year=1997|pages=254–258 | volume=94 | issue=1 | pmid=8990195 | doi=10.1073/pnas.94.1.254| pmc=19306|bibcode = 1997PNAS...94..254P }}</ref>


HIV-1 associated dementia ([[HAD]]) is a metabolic encephalopathy induced by HIV infection and fueled by immune activation of brain [[macrophages]] and [[microglia]] (Gray et al., 2001). These cells are actively infected with HIV and secrete [[neurotoxins]] of both host and viral origin. Specific neurologic impairments are manifested by cognitive, behavioral, and motor abnormalities that occur after years of HIV infection and is associated with low [[CD4+]] T cell levels and high plasma viral loads. Prevalence is between 15-30% in Western countries (Heaton et al., 1995; White et al., 1995) and has only been seen in 1-2% of India based infections (Satischandra et al., 2000; Wadia et al., 2001).
The pathophysiology of AIDS is complex. Ultimately, HIV causes AIDS by depleting CD4<sup>+</sup> T helper lymphocytes. This weakens the immune system and allows [[opportunistic infection]]s. T lymphocytes are essential to the immune response for defense against opportunistic infections and the inhibition of neoplastic proliferation. The mechanism of CD4<sup>+</sup>T cell depletion differs in the acute and chronic phases.<ref name="pmid16679064">{{Cite journal|author=Hel Z, McGhee JR, Mestecky J |title=HIV infection: first battle decides the war|journal=Trends Immunol. |volume=27 |issue=6 |pages=274–81 |date=June 2006 |pmid=16679064|doi=10.1016/j.it.2006.04.007 |url=}}</ref>  During the acute phase, HIV-induced cell lysis and killing of infected cells by [[cytotoxic T cell]]s accounts for CD4<sup>+</sup> T cell depletion, although [[apoptosis]] may also be a factor. During the chronic phase, the consequences of generalized immune activation coupled with the gradual loss of the ability of the immune system to generate new T cells appear to account for the slow decline in CD4<sup>+</sup> T cell numbers. Although the symptoms of immune deficiency characteristic of AIDS do not appear for years after a person is infected, the bulk of CD4<sup>+</sup> T cell loss occurs during the first weeks of infection, especially in the intestinal mucosa, which harbors the majority of the lymphocytes found in the body.<ref name="pmid15365095">{{Cite journal|author=Mehandru S, Poles MA, Tenner-Racz K, Horowitz A, Hurley A, Hogan C, Boden D, Racz P, Markowitz M |title=Primary HIV-1 infection is associated with preferential depletion of CD4<sup>+</sup> T lymphocytes from effector sites in the gastrointestinal tract |journal=J. Exp. Med. |volume=200 |issue=6 |pages=761–70 |date=September 2004|pmid=15365095 |doi=10.1084/jem.20041196 |url= |pmc=2211967}}</ref> The reason for the preferential loss of mucosal CD4<sup>+</sup> T cells is that a majority of mucosal CD4<sup>+</sup> T cells express the CCR5 coreceptor, whereas a small fraction of CD4<sup>+</sup> T cells in the bloodstream do so.<ref name="pmid15365096">{{Cite journal|author=Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, Beilman GJ, Nguyen PL, Khoruts A, Larson M, Haase AT, Douek DC |title=CD4<sup>+</sup> T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract |journal=J. Exp. Med. |volume=200 |issue=6 |pages=749–59 |date=September 2004 |pmid=15365096|doi=10.1084/jem.20040874 |url= |pmc=2211962}}</ref>  HIV seeks out and destroys CCR5 expressing CD4<sup>+</sup> cells during acute infection. A vigorous immune response eventually controls the infection and initiates the clinically latent phase. However, CD4<sup>+</sup> T cells in mucosal tissues remain depleted throughout the infection, although enough remain to initially ward off life-threatening infections.


===D. HIV-associated malignancies ===
Continuous HIV replication results in a state of generalized immune activation persisting throughout the chronic phase.<ref name="pmid18161758">{{Cite journal|author=Appay V, Sauce D |title=Immune activation and inflammation in HIV-1 infection: causes and consequences |journal=J. Pathol. |volume=214 |issue=2|pages=231–41 |date=January 2008 |pmid=18161758 |doi=10.1002/path.2276 |url=}}</ref> Immune activation, which is reflected by the increased activation state of immune cells and release of proinflammatory [[cytokine]]s, results from the activity of several HIV gene products and the immune response to ongoing HIV replication. Another cause is the breakdown of the immune surveillance system of the mucosal barrier caused by the depletion of mucosal CD4<sup>+</sup> T cells during the acute phase of disease.<ref name="pmid17115046">{{Cite journal|author=Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, Kazzaz Z, Bornstein E, Lambotte O, Altmann D, Blazar BR, Rodriguez B, Teixeira-Johnson L, Landay A, Martin JN, Hecht FM, Picker LJ, Lederman MM, Deeks SG, Douek DC|title=Microbial translocation is a cause of systemic immune activation in chronic HIV infection|journal=Nat. Med. |volume=12 |issue=12 |pages=1365–71 |date=December 2006 |pmid=17115046|doi=10.1038/nm1511 |url=}}</ref>


Patients with HIV infection are susceptible to a number of malignancies (Yarchoan et al., 2005). The most common is [[Kaposi's sarcoma]], and the appearance of this tumor in young gay men in New York in 1981 was one of the first signals of the AIDS epidemic. In addition, patients with HIV infection have a higher incidence of certain high grade [[B cell lymphoma]]s, especially Burkitt-like and [[large cell lymphoma]]s. These tumors, as well as aggressive cervical cancer in women, confer a diagnosis of AIDS in patients with HIV infection.
This results in the systemic exposure of the immune system to microbial components of the gut’s normal flora, which in a healthy person is kept in check by the mucosal immune system. The activation and proliferation of T cells that results from immune activation provides fresh targets for HIV infection. However, direct killing by HIV alone cannot account for the observed depletion of CD4<sup>+</sup> T cells since only 0.01–0.10% of CD4<sup>+</sup> T cells in the blood are infected.
====Major Mechanisms of Disease====
HIV causes major immune compromise by directly altering CD4 T-cell number and function. Some of the potential mechanisms by which the virus affects these cells include:<ref name="pmid8093551">{{cite journal| author=Pantaleo G, Graziosi C, Fauci AS| title=New concepts in the immunopathogenesis of human immunodeficiency virus infection. | journal=N Engl J Med | year= 1993 | volume= 328 | issue= 5 | pages= 327-35 | pmid=8093551 | doi=10.1056/NEJM199302043280508 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8093551  }} </ref>
*'''HIV-mediated cell destruction'''
Single-cell killing is secondary to the direct cytopathic effects of the virus. It results from the inhibition of protein synthesis or from the accumulation of viral DNA.
*'''HIV-mediated syncytia formation'''
Syncytia are created by the fusion of multiple cells to create giant multinucleated cells. HIV is capable of inducing syncytia formation particularly in the accelerated phase of the disease. This allows infection of new cells while evading immune control.
*'''HIV-mediated autoimmunity'''
Both HLA-DR and HLA-DQ, two important HLA paralogues that are partly homologous in structure to gp120 and gp41 proteins of HIV type. Antibodies to these proteins may cross-react with the host MHC class II molecules.
*'''Anergy due to inappropriate cell signaling through gp120-CD4 interaction'''
Antigen-antibody complexes of gp120 are capable, in vitro, of inducing anergy in CD4 T-cells. These complexes bind the CD4 molecules making these cells refractory to further antigenic stimulation by CD3 activation.
*'''Superantigen-mediated disturbance of T-cell subgroups'''
Unlike regular antigens that bind the MHCII groove, superantigens bind to a specific variable region of the β chain of the T-cell receptor (TCR) and lead to massive stimulation of T-cells. HIV may encode superantigens that cause T-cell activation rendering these cells more susceptible to infection. <ref name="pmid8093551">{{cite journal| author=Pantaleo G, Graziosi C, Fauci AS| title=New concepts in the immunopathogenesis of human immunodeficiency virus infection. | journal=N Engl J Med | year= 1993 | volume= 328 | issue= 5 | pages= 327-35 | pmid=8093551 | doi=10.1056/NEJM199302043280508 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8093551  }} </ref>


===E. The Major Dermatological illnesses ===
{| style="float:right"
'''AIDS-associated Kaposi sarcoma''' or '''KS-AIDS''' presents with cutaneous [[lesion]]s that begin as one or several red to purple-red [[macule]]s, rapidly progressing to [[papule]]s, [[Nodule_(dermatology)|nodule]]s, and [[plaque_(dermatology)|plaque]]s, with a predilection for the head, neck, trunk, and [[mucous membrane]]s.
|[[Image:TEM HIV.jpg|left|thumb|200px|Thin-section transmission [[electron micrograph]] (TEM) depicting the ultrastructural details of two "human immunodeficiency virus" (HIV)  
[[virions - Source: https://www.cdc.gov/]]]]
|}


===HIV-specific Immune Response===
Although the HIV-specific immune response is important to control viral replication and spread initially, it plays an important role in the immunopathogenesis in the chronic phase of the disease. The immune response against HIV aims to eliminate HIV-infected cells further accelerating the progressive deterioration of the immune system.<ref name="pmid8093551">{{cite journal| author=Pantaleo G, Graziosi C, Fauci AS| title=New concepts in the immunopathogenesis of human immunodeficiency virus infection. | journal=N Engl J Med | year= 1993 | volume= 328 | issue= 5 | pages= 327-35 | pmid=8093551 | doi=10.1056/NEJM199302043280508 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8093551  }} </ref>


<gallery>  
===Role of GALT in Pathogenesis===
 
*Port of entry for HIV infection is mostly through direct blood [[inoculation]] or exposure through [[genital]] [[mucosa]]l surface. The [[gastrointestinal tract]] contains a large amount of [[lymphoid tissue]], making it an ideal place for [[replication]] of Human Immunodeficiency Virus. [[GALT]] plays a role in HIV replication. <ref name="pmid11242193">{{cite journal |author=Talal AH, Irwin CE, Dieterich DT, Yee H, Zhang L |title=Effect of HIV-1 infection on lymphocyte proliferation in gut-associated lymphoid tissue |journal=J. Acquir. Immune Defic. Syndr. |volume=26 |issue=3 |pages=208–17 |year=2001 |month=March |pmid=11242193 |doi= |url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=1525-4135&volume=26&issue=3&spage=208 |accessdate=2012-05-25}}</ref>
 
* GALT has been found to have the following characteristics:
Image:Kaposi's_sarcoma.jpg|Kaposi's sarcoma lesion commonly found in patients with stage IV AIDS
**Site of early viral seeding.
**Establishment of the pro-viral [[natural reservoir|reservoir]].
*The proviral GALT reservoir contributes to the following:
#Difficulty in controlling the infection.
#Difficulty in reducing the level of HIV provirus through sustained ART.<ref name="pmid16936559">{{cite journal |author=Poles MA, Boscardin WJ, Elliott J, Taing P, Fuerst MM, McGowan I, Brown S, Anton PA |title=Lack of decay of HIV-1 in gut-associated lymphoid tissue reservoirs in maximally suppressed individuals |journal=J. Acquir. Immune Defic. Syndr. |volume=43 |issue=1 |pages=65–8 |year=2006 |month=September |pmid=16936559 |doi=10.1097/01.qai.0000230524.71717.14 |url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=1525-4135&volume=43&issue=1&spage=65 |accessdate=2012-05-25}}</ref> Various studies measuring the CD4<sup>4</sup> in GALT, have shown the relatively less reconstitution with ART, than that observed in peripheral blood.<ref name="pmid14557656">{{cite journal |author=Guadalupe M, Reay E, Sankaran S, Prindiville T, Flamm J, McNeil A, Dandekar S |title=Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy |journal=J. Virol. |volume=77 |issue=21 |pages=11708–17 |year=2003 |month=November |pmid=14557656 |pmc=229357 |doi= |url=http://jvi.asm.org/cgi/pmidlookup?view=long&pmid=14557656 |accessdate=2012-05-25}}</ref><ref name="pmid12719554">{{cite journal |author=Shacklett BL, Cox CA, Sandberg JK, Stollman NH, Jacobson MA, Nixon DF |title=Trafficking of human immunodeficiency virus type 1-specific CD8+ T cells to gut-associated lymphoid tissue during chronic infection |journal=J. Virol. |volume=77 |issue=10 |pages=5621–31 |year=2003 |month=May |pmid=12719554 |pmc=154016 |doi= |url=http://jvi.asm.org/cgi/pmidlookup?view=long&pmid=12719554 |accessdate=2012-05-25}}</ref>


==Gallery==


Image:Kaposi’s sarcoma intraoral AIDS 072 lores.jpg|Intraoral Kaposi’s sarcoma lesion with an overlying [[candidiasis]] infection
<gallery>


</gallery>
Image: HIV_structure01.jpeg| '''HIV structure'''. <SMALL><SMALL>''[http://phil.cdc.gov/phil/home.asp From Public Health Image Library (PHIL).] ''<ref name=PHIL> {{Cite web | title = Public Health Image Library (PHIL) | url = http://phil.cdc.gov/phil/home.asp}}</ref></SMALL></SMALL>
===Transmission===
The three main [[transmission]] routes of HIV are sexual contact, exposure to infected body fluids or tissues, and from mother to [[fetus]] or child during [[perinatal]] period. It is possible to find HIV in the [[saliva]], [[tears]], and [[urine]] of infected individuals, but there are no recorded cases of infection by these [[secretion]]s, and the risk of infection is negligible.


Transmission of HIV depends on the infectiousness of the index case and the susceptibility of the uninfected partner. Exposure to infected body fluids is particularly relevant to [[Intravenous drug use (recreational)|intravenous drug]] users, [[Haemophilia|hemophiliacs]] and recipients of [[blood transfusion]]s and blood products. Sharing and reusing [[syringe]]s contaminated with HIV-infected blood represents a major risk for infection with not only HIV, but also [[hepatitis B]] and [[hepatitis C]].
Image: HIV_pathophysiology01.jpeg| '''HIV pathophysiology.''' <SMALL><SMALL>''[http://phil.cdc.gov/phil/home.asp From Public Health Image Library (PHIL).] ''<ref name=PHIL> {{Cite web | title = Public Health Image Library (PHIL) | url = http://phil.cdc.gov/phil/home.asp}}</ref></SMALL></SMALL>


The transmission of the virus from the mother to the child can occur ''[[in utero]]'' during the last weeks of pregnancy and at childbirth.
</gallery>
==Related Chapters==
* [[AIDS defining clinical condition]]
* [[Acute HIV infection]]


==References==
==References==
{{reflist|2}}
{{reflist|2}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}


[[Category:HIV/AIDS]]
[[Category:HIV/AIDS]]
[[Category:Disease]]
[[Category:Disease]]
[[Category:Immune system disorders]]
[[Category:Immune system disorders]]
[[Category:Infectious disease]]
[[Category:Viral diseases]]
[[category:viral diseases]]
[[Category:Pandemics]]
[[Category:Pandemics]]
[[Category:Sexually transmitted infections]]
[[Category:Sexually transmitted infections]]
Line 112: Line 198:
[[Category:AIDS origin hypotheses]]
[[Category:AIDS origin hypotheses]]
[[Category:Medical disasters]]
[[Category:Medical disasters]]
[[Category:Acronyms]]
[[Category:Immunodeficiency]]
[[Category:Immunodeficiency]]
[[Category:Microbiology]]
[[Category:Microbiology]]
 
[[Category:Emergency mdicine]]
{{WikiDoc Help Menu}}
[[Category:Up-To-Date]]
{{WikiDoc Sources}}
[[Category:Infectious disease]]

Latest revision as of 22:12, 29 July 2020

https://https://www.youtube.com/watch?v=5g1ijpBI6Dk%7C350}}

Sexually transmitted diseases Main Page

AIDS Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating AIDS from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

HIV Opportunistic Infections

HIV Coinfections

HIV and Pregnancy

HIV Infection in Infants

Diagnosis

Diagnostic Study of Choice

AIDS Case Definition

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Nutrition
Drug Resistance

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

HIV Vaccine

Case Studies

Case #1

HIV AIDS pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of HIV AIDS pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on HIV AIDS pathophysiology

CDC on HIV AIDS pathophysiology

HIV AIDS pathophysiology in the news

Blogs on HIV AIDS pathophysiology

Directions to Hospitals Treating AIDS

Risk calculators and risk factors for HIV AIDS pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2], Jesus Rosario Hernandez, M.D. [3]

Overview

HIV causes acquired immunodeficiency syndrome by depleting CD4+ T helper lymphocytes. The virus is acquired by either sexual contact, exposure to contaminated blood, or mother-to-child transmission. Once the virus is acquired, it disseminates to the majority of lymphoid organs, where it enters a period of rapid viral replication. This leads to the acute phase of the infection, which is characterized by a very elevated viral titer and an acute drop in CD4 T-lymphocyte count. As the immune response mounts, viral replication and the CD4-cell depletion rate drops. The immune system continues to deteriorate, but at a slower pace. This is known as the chronic phase of HIV infection. The HIV virus causes CD4-cell death by a variety of mechanisms including cytopathic single-cell destruction, syncytia formation, autoimmunity, and superantigen formation.[1]

Pathophysiology

HIV transmission

Estimated risk for acquisition of HIV-1 by exposure route[2]
Exposure Route Estimated infections
per 10,000 exposures
to an infected source
Blood Transfusion 9,000[3]
Childbirth 2,500[4]
Needle-sharing injection drug use 67[5]
Receptive anal intercourse 50[6][7]
Percutaneous needle stick 30[8]
Receptive penile-vaginal intercourse 10[6][7][9]
Insertive anal intercourse 6.5[6][7]
Insertive penile-vaginal intercourse 5[6][7]
Receptive fellatio 1[7]
Insertive fellatio 0.5[7]
Assuming no condom use.

Since the beginning of the pandemic, three main transmission routes for HIV have been identified: sexual route, blood or blood product route, and mother-to-child transmission.
Sexual route

  • The majority of HIV infections are acquired through unprotected sexual relations. Sexual transmission can occur when infected sexual secretions of one partner come into contact with the genital, oral, or rectal mucous membranes of another.

Blood or blood product route

  • This transmission route can account for infections in intravenous drug users, hemophiliacs and recipients of blood transfusions (though most transfusions are checked for HIV in the developed world) and blood products.
  • It is also of concern for persons receiving medical care in regions where there is prevalent substandard hygiene in the use of injection equipment, such as the reuse of needles in Third World countries. HIV can also be spread through the sharing of needles.
  • Health care workers such as nurses, laboratory workers, and doctors, have also been infected, although this occurs more rarely. People who give and receive tattoos, piercings, and scarification procedures can also be at risk of infection.

Mother-to-child transmission (MTCT)

  • The transmission of the virus from the mother to the child can occur in utero during pregnancy and intrapartum at childbirth. In the absence of treatment, the transmission rate between the mother and child is around 25%.[4] However, where combination antiretroviral drug treatment and Cesarian section are available, this risk can be reduced to as low as 1%.[4] Breast feeding also presents a risk of infection for the baby.
  • HIV-2 is transmitted much less frequently by the MTCT and sexual route than HIV-1.

Other Considerations

  • HIV has been found at low concentrations in the saliva, tears and urine of infected individuals, but there are no recorded cases of infection by these secretions and the potential risk of transmission is negligible.[10]
  • The use of physical barriers such as the latex condom is widely advocated to reduce the sexual transmission of HIV. Spermicide, when used alone or with vaginal contraceptives like a diaphragm, actually increases the male to female transmission rate due to inflammation of the vagina; it should not be considered a barrier to infection.[11]
  • A panel of experts convened by WHO and the UNAIDS Secretariat has "recommended that male circumcision now be recognized as an additional important intervention to reduce the risk of heterosexually acquired HIV infection in men."[12]
  • Research is clarifying whether there is a historical relationship between rates of male circumcision and rates of HIV in differing social and cultural contexts. Previously, Siegfried et al. suggested that it was possible that the correlation between circumcision and HIV in observational studies may be due to confounding factors, and remarked that the randomized controlled trials would therefore provide "essential evidence" about the effects of circumcision.[13]
  • There is little data on circumcision's effect on HIV risk with homosexual men and it is still being studied. A study of foreign and American men by scientists at the University of Washington, Seattle concluded: "Uncircumcised homosexual men in Seattle had a two fold increased risk of HIV infection.
  • If the relative risk that we observed in Seattle were also present in other populations, the population attributable risk of uncircumcised status for HIV in homosexual men would be 40%, i.e., 40% of homosexual transmission of HIV could be potentially preventable with universal circumcision."[4]
  • A study of Australian men headed by David Templeton, MD, from the University of New South Wales found "no relationship at all between circumcision and HIV seroconversion in" homosexual men. Templeton theorizes that this may be because most HIV occurs "following receptive rather than insertive intercourse," as he finds data on circumcision's effect on heterosexual men "compelling".[14] South African medical experts are concerned that the repeated use of unsterilized blades in the ritual (not medical) circumcision of adolescent boys may be spreading HIV.[15]

Viral Pathogenesis

After the virus is acquired, a period of rapid viral replication ensues, leading to abundant viremia. During primary infection, the level of HIV may reach several million virus particles per milliliter of blood.[16] This response is accompanied by a marked drop in the numbers of circulating CD4+ T cells. This acute viremia is associated in virtually all people with the activation of CD8+ T cells, which kill HIV-infected cells, and subsequently with antibody production, or seroconversion. The CD8+ T cell response is thought to be important in controlling virus levels, which peak and then decline, as the CD4+ T cell counts rebound. A good CD8+ T cell response has been linked to slower disease progression and a better prognosis, though it does not eliminate the virus.[17]

The pathophysiology of AIDS is complex. Ultimately, HIV causes AIDS by depleting CD4+ T helper lymphocytes. This weakens the immune system and allows opportunistic infections. T lymphocytes are essential to the immune response for defense against opportunistic infections and the inhibition of neoplastic proliferation. The mechanism of CD4+T cell depletion differs in the acute and chronic phases.[18] During the acute phase, HIV-induced cell lysis and killing of infected cells by cytotoxic T cells accounts for CD4+ T cell depletion, although apoptosis may also be a factor. During the chronic phase, the consequences of generalized immune activation coupled with the gradual loss of the ability of the immune system to generate new T cells appear to account for the slow decline in CD4+ T cell numbers. Although the symptoms of immune deficiency characteristic of AIDS do not appear for years after a person is infected, the bulk of CD4+ T cell loss occurs during the first weeks of infection, especially in the intestinal mucosa, which harbors the majority of the lymphocytes found in the body.[19] The reason for the preferential loss of mucosal CD4+ T cells is that a majority of mucosal CD4+ T cells express the CCR5 coreceptor, whereas a small fraction of CD4+ T cells in the bloodstream do so.[20] HIV seeks out and destroys CCR5 expressing CD4+ cells during acute infection. A vigorous immune response eventually controls the infection and initiates the clinically latent phase. However, CD4+ T cells in mucosal tissues remain depleted throughout the infection, although enough remain to initially ward off life-threatening infections.

Continuous HIV replication results in a state of generalized immune activation persisting throughout the chronic phase.[21] Immune activation, which is reflected by the increased activation state of immune cells and release of proinflammatory cytokines, results from the activity of several HIV gene products and the immune response to ongoing HIV replication. Another cause is the breakdown of the immune surveillance system of the mucosal barrier caused by the depletion of mucosal CD4+ T cells during the acute phase of disease.[22]

This results in the systemic exposure of the immune system to microbial components of the gut’s normal flora, which in a healthy person is kept in check by the mucosal immune system. The activation and proliferation of T cells that results from immune activation provides fresh targets for HIV infection. However, direct killing by HIV alone cannot account for the observed depletion of CD4+ T cells since only 0.01–0.10% of CD4+ T cells in the blood are infected.

Major Mechanisms of Disease

HIV causes major immune compromise by directly altering CD4 T-cell number and function. Some of the potential mechanisms by which the virus affects these cells include:[1]

  • HIV-mediated cell destruction

Single-cell killing is secondary to the direct cytopathic effects of the virus. It results from the inhibition of protein synthesis or from the accumulation of viral DNA.

  • HIV-mediated syncytia formation

Syncytia are created by the fusion of multiple cells to create giant multinucleated cells. HIV is capable of inducing syncytia formation particularly in the accelerated phase of the disease. This allows infection of new cells while evading immune control.

  • HIV-mediated autoimmunity

Both HLA-DR and HLA-DQ, two important HLA paralogues that are partly homologous in structure to gp120 and gp41 proteins of HIV type. Antibodies to these proteins may cross-react with the host MHC class II molecules.

  • Anergy due to inappropriate cell signaling through gp120-CD4 interaction

Antigen-antibody complexes of gp120 are capable, in vitro, of inducing anergy in CD4 T-cells. These complexes bind the CD4 molecules making these cells refractory to further antigenic stimulation by CD3 activation.

  • Superantigen-mediated disturbance of T-cell subgroups

Unlike regular antigens that bind the MHCII groove, superantigens bind to a specific variable region of the β chain of the T-cell receptor (TCR) and lead to massive stimulation of T-cells. HIV may encode superantigens that cause T-cell activation rendering these cells more susceptible to infection. [1]

Thin-section transmission electron micrograph (TEM) depicting the ultrastructural details of two "human immunodeficiency virus" (HIV) virions - Source: https://www.cdc.gov/

HIV-specific Immune Response

Although the HIV-specific immune response is important to control viral replication and spread initially, it plays an important role in the immunopathogenesis in the chronic phase of the disease. The immune response against HIV aims to eliminate HIV-infected cells further accelerating the progressive deterioration of the immune system.[1]

Role of GALT in Pathogenesis

  • Port of entry for HIV infection is mostly through direct blood inoculation or exposure through genital mucosal surface. The gastrointestinal tract contains a large amount of lymphoid tissue, making it an ideal place for replication of Human Immunodeficiency Virus. GALT plays a role in HIV replication. [23]
  • GALT has been found to have the following characteristics:
    • Site of early viral seeding.
    • Establishment of the pro-viral reservoir.
  • The proviral GALT reservoir contributes to the following:
  1. Difficulty in controlling the infection.
  2. Difficulty in reducing the level of HIV provirus through sustained ART.[24] Various studies measuring the CD44 in GALT, have shown the relatively less reconstitution with ART, than that observed in peripheral blood.[25][26]

Gallery

References

  1. ↑ 1.0 1.1 1.2 1.3 Pantaleo G, Graziosi C, Fauci AS (1993). "New concepts in the immunopathogenesis of human immunodeficiency virus infection". N Engl J Med. 328 (5): 327–35. doi:10.1056/NEJM199302043280508. PMID 8093551.
  2. ↑ Smith, D. K., Grohskopf, L. A., Black, R. J., Auerbach, J. D., Veronese, F., Struble, K. A., Cheever, L., Johnson, M., Paxton, L. A., Onorato, I. A. and Greenberg, A. E. (2005). "Antiretroviral Postexposure Prophylaxis After Sexual, Injection-Drug Use, or Other Nonoccupational Exposure to HIV in the United States". MMWR. 54 (RR02): 1–20.
  3. ↑ Donegan, E., Stuart, M., Niland, J. C., Sacks, H. S., Azen, S. P., Dietrich, S. L., Faucett, C., Fletcher, M. A., Kleinman, S. H., Operskalski, E. A.; et al. (1990). "Infection with human immunodeficiency virus type 1 (HIV-1) among recipients of antibody-positive blood donations". Ann. Intern. Med. 113 (10): 733–739. PMID 2240875.
  4. ↑ 4.0 4.1 4.2 Coovadia, H. (2004). "Antiretroviral agents—how best to protect infants from HIV and save their mothers from AIDS". N. Engl. J. Med. 351 (3): 289–292. PMID 15247337.
  5. ↑ Kaplan, E. H. and Heimer, R. (1995). "HIV incidence among New Haven needle exchange participants: updated estimates from syringe tracking and testing data". J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 10 (2): 175–176. PMID 7552482.
  6. ↑ 6.0 6.1 6.2 6.3 European Study Group on Heterosexual Transmission of HIV (1992). "Comparison of female to male and male to female transmission of HIV in 563 stable couples". BMJ. 304 (6830): 809–813. PMID 1392708.
  7. ↑ 7.0 7.1 7.2 7.3 7.4 7.5 Varghese, B., Maher, J. E., Peterman, T. A., Branson, B. M. and Steketee, R. W. (2002). "Reducing the risk of sexual HIV transmission: quantifying the per-act risk for HIV on the basis of choice of partner, sex act, and condom use". Sex. Transm. Dis. 29 (1): 38–43. PMID 11773877.
  8. ↑ Bell, D. M. (1997). "Occupational risk of human immunodeficiency virus infection in healthcare workers: an overview". Am. J. Med. 102 (5B): 9–15. PMID 9845490.
  9. ↑ Leynaert, B., Downs, A. M. and de Vincenzi, I. (1998). "Heterosexual transmission of human immunodeficiency virus: variability of infectivity throughout the course of infection. European Study Group on Heterosexual Transmission of HIV". Am. J. Epidemiol. 148 (1): 88–96. PMID 9663408.
  10. ↑ Lifson AR (1988). "Do alternate modes for transmission of human immunodeficiency virus exist? A review". JAMA. 259 (9): 1353–6. PMID 2963151.
  11. ↑ "Should spermicides be used with condoms?". Condom Brochure, FDA OSHI HIV STDs. Retrieved 2006-10-23.
  12. ↑ WHO (2007). "WHO and UNAIDS announce recommendations from expert consultation on male circumcision for HIV prevention". WHO.int. Retrieved 2007-07-13.
  13. ↑ Siegfried, N., Muller, M., Deeks, J., Volmink, J., Egger, M., Low, N., Walker, S. and Williamson, P. (2005). "HIV and male circumcision--a systematic review with assessment of the quality of studies". Lancet Infect. Dis. 5 (3): 165–173. PMID 15766651.
  14. ↑ http://www.medscape.com/viewarticle/560823
  15. ↑ Various (2005). "Repeated Use of Unsterilized Blades in Ritual Circumcision Might Contribute to HIV Spread in S. Africa, Doctors Say". Kaisernetwork.org. Retrieved 2006-03-28.
  16. ↑ Piatak, M., Jr, Saag, M. S., Yang, L. C., Clark, S. J., Kappes, J. C., Luk, K. C., Hahn, B. H., Shaw, G. M. and Lifson, J.D. (1993). "High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR". Science. 259 (5102): 1749–1754. Bibcode:1993Sci...259.1749P. doi:10.1126/science.8096089. PMID 8096089.
  17. ↑ Pantaleo G, Demarest JF, Schacker T, Vaccarezza M, Cohen OJ, Daucher M, Graziosi C, Schnittman SS, Quinn TC, Shaw GM, Perrin L, Tambussi G, Lazzarin A, Sekaly RP, Soudeyns H, Corey L, Fauci AS. (1997). "The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia". Proc Natl Acad Sci U S A. 94 (1): 254–258. Bibcode:1997PNAS...94..254P. doi:10.1073/pnas.94.1.254. PMC 19306. PMID 8990195.
  18. ↑ Hel Z, McGhee JR, Mestecky J (June 2006). "HIV infection: first battle decides the war". Trends Immunol. 27 (6): 274–81. doi:10.1016/j.it.2006.04.007. PMID 16679064.
  19. ↑ Mehandru S, Poles MA, Tenner-Racz K, Horowitz A, Hurley A, Hogan C, Boden D, Racz P, Markowitz M (September 2004). "Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract". J. Exp. Med. 200 (6): 761–70. doi:10.1084/jem.20041196. PMC 2211967. PMID 15365095.
  20. ↑ Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, Beilman GJ, Nguyen PL, Khoruts A, Larson M, Haase AT, Douek DC (September 2004). "CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract". J. Exp. Med. 200 (6): 749–59. doi:10.1084/jem.20040874. PMC 2211962. PMID 15365096.
  21. ↑ Appay V, Sauce D (January 2008). "Immune activation and inflammation in HIV-1 infection: causes and consequences". J. Pathol. 214 (2): 231–41. doi:10.1002/path.2276. PMID 18161758.
  22. ↑ Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, Kazzaz Z, Bornstein E, Lambotte O, Altmann D, Blazar BR, Rodriguez B, Teixeira-Johnson L, Landay A, Martin JN, Hecht FM, Picker LJ, Lederman MM, Deeks SG, Douek DC (December 2006). "Microbial translocation is a cause of systemic immune activation in chronic HIV infection". Nat. Med. 12 (12): 1365–71. doi:10.1038/nm1511. PMID 17115046.
  23. ↑ Talal AH, Irwin CE, Dieterich DT, Yee H, Zhang L (2001). "Effect of HIV-1 infection on lymphocyte proliferation in gut-associated lymphoid tissue". J. Acquir. Immune Defic. Syndr. 26 (3): 208–17. PMID 11242193. Retrieved 2012-05-25. Unknown parameter |month= ignored (help)
  24. ↑ Poles MA, Boscardin WJ, Elliott J, Taing P, Fuerst MM, McGowan I, Brown S, Anton PA (2006). "Lack of decay of HIV-1 in gut-associated lymphoid tissue reservoirs in maximally suppressed individuals". J. Acquir. Immune Defic. Syndr. 43 (1): 65–8. doi:10.1097/01.qai.0000230524.71717.14. PMID 16936559. Retrieved 2012-05-25. Unknown parameter |month= ignored (help)
  25. ↑ Guadalupe M, Reay E, Sankaran S, Prindiville T, Flamm J, McNeil A, Dandekar S (2003). "Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy". J. Virol. 77 (21): 11708–17. PMC 229357. PMID 14557656. Retrieved 2012-05-25. Unknown parameter |month= ignored (help)
  26. ↑ Shacklett BL, Cox CA, Sandberg JK, Stollman NH, Jacobson MA, Nixon DF (2003). "Trafficking of human immunodeficiency virus type 1-specific CD8+ T cells to gut-associated lymphoid tissue during chronic infection". J. Virol. 77 (10): 5621–31. PMC 154016. PMID 12719554. Retrieved 2012-05-25. Unknown parameter |month= ignored (help)
  27. ↑ 27.0 27.1 "Public Health Image Library (PHIL)".


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=HIV_AIDS_pathophysiology&oldid=1639417"